FABENTECH is a company headquartered in France. Brouky records 1 investor associated with the company.
FABENTECH develops and produces emergency treatments to counteract bioterrorism risks and priority emerging infectious diseases by using a proprietary platform to generate purified polyclonal antibody fragments that neutralize viruses and toxins.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.